A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

被引：1
|
作者：
Lu, S. [1 ]
Zhou, J. [2 ]
Niu, X. [3 ]
Chen, M. [4 ]
Hua, Y. [4 ]
Su, W. [4 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Shanghai, Peoples R China
[2] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[4] Hutchison Medipharma, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Fruquintinib; non-small cell lung cancer; gefitinib;
D O I：
10.1016/j.jtho.2017.09.301
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
JCES 01.12
引用
收藏
页码：S1735 / S1735
页数：1
相关论文
共 50 条
  • [1] A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations
    Saltos, Andreas N.
    Creelan, Ben C.
    Tanvetyanon, Tawee
    Chiappori, Alberto A.
    Antonia, Scott J.
    Shafique, Michael R.
    Ugrenovic-Petrovic, Milijana
    Sansil, Samer
    Neuger, Anthony
    Ozakinci, Hilal
    Boyle, Theresa A.
    Kim, Jongphil
    Haura, Eric B.
    Gray, Jhanelle E.
    LUNG CANCER, 2023, 183
  • [2] Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
    Rossi, Antonio
    Galetta, Domenico
    CANCERS, 2022, 14 (03)
  • [3] A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test
    Choi, Moon Ki
    Hong, Jung Yong
    Chang, Won Jin
    Kim, Moon Jin
    Kim, Sung Min
    Jung, Hyun Ae
    Do, In-Gu
    Choi, Yoon-la
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (06) : 1229 - 1236
  • [4] A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test
    Moon Ki Choi
    Jung Yong Hong
    Won Jin Chang
    Moon Jin Kim
    Sung Min Kim
    Hyun Ae Jung
    In-Gu Do
    Yoon-la Choi
    Jong-Mu Sun
    Jin Seok Ahn
    Keunchil Park
    Myung-Ju Ahn
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 1229 - 1236
  • [5] A Phase II Multicentre Study of Gefitinib in Combination with Irradiation Followed by Chemotherapy in Patients with Inoperable Stage III NSCLC
    Levy, Antonin
    Bardet, Etienne
    Artignan, Xavier
    Verrelle, Pierre
    Le Pechoux, Cecile
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S572 - S572
  • [6] Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study
    Thongprasert, Sumitra
    Geater, Sarayut L.
    Clement, Dana
    Abdelaziz, Amr
    Reyes-Igama, Jasmin
    Jovanovic, Dragana
    Alexandru, Aurelia
    Schenker, Michael
    Sriuranpong, Virote
    Serwatowski, Piotr
    Suresh, Sheethal
    Cseh, Agnieszka
    Gaafar, Rabab
    LUNG CANCER MANAGEMENT, 2019, 8 (03)
  • [7] Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients
    Wang, Chunsheng
    Zhao, Kewei
    Hu, Shanliang
    Dong, Wei
    Gong, Yan
    Li, Minghuan
    Xie, Conghua
    LUNG CANCER, 2022, 172 : 86 - 93
  • [8] Phase II Study of Biweekly Carboplatin, Gemcitabine, and Bevacizumab as First-line Treatment in Patients with Stage IIIB/IV NSCLC
    Dudek, Arkadiusz Z.
    Kumar, Priya
    Thaw, Sunn Sunn H.
    Cao, Qing
    Pawloski, Pamala
    Larson, Timothy
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (02): : 140 - 143
  • [9] A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Ukena, D
    Berg, M
    Leutz, M
    Zell, L
    Schlimmer, P
    Sybrecht, GW
    LUNG CANCER, 1998, 19 (01) : 31 - 36
  • [10] Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study
    Ma, Yuxiang
    Chen, Qun
    Zhang, Yang
    Xue, Jinhui
    Liu, Qianwen
    Zhao, Yuanyuan
    Yang, Yunpeng
    Huang, Yan
    Fang, Wenfeng
    Hou, Zhiguo
    Li, Shaorong
    Wang, Jing
    Zhang, Li
    Zhao, Hongyun
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 92 (05) : 411 - 418
12345